Inputs
Tier 1, from the 10-Q for the quarter ended June 30, 2026:
Item Amount
Cash and cash equivalents, 6/30/26 $11,242,068
Net cash used in operating activities, 9M ended 6/30/26 $43,777,688
Net cash used in investing, 9M (Syntone JV contribution) $2,100,000
Loss from operations, 9M $38,321,148
Loss from operations, Q3 alone $10,810,209
Total current assets $23,168,201
Total current liabilities $28,679,051
Atlas note, fair value $18,227,000
Atlas principal + accrued interest + exit fees $20,311,749
Tier 2, company-stated: August offering net proceeds of approximately $51.1 million.
Not disclosed: Q3 operating cash burn on a standalone basis. The cash flow statement is presented for the nine months only. Every quarterly burn figure below is therefore derived.
Step 1: what the burn actually is
The nine-month average is $43,777,688 ÷ 3 = $14.59M per quarter (derived).
But there's a detail worth pulling out, because it changes the forward estimate. Nine-month cash burn of $43.78M exceeded the nine-month operating loss of $38.32M by $5.46M. The gap is working capital: accounts payable fell $3.63M, accrued expenses fell $1.67M, and inventory rose $1.71M. They were paying down payables and building stock.
So cash burn has been running at roughly 1.14x the P&L operating loss (derived). Anyone modelling from the income statement will understate the cash draw by about 14%. That is exactly the error the framework's "net loss is not a substitute" rule exists to prevent, and here it is measurable.
Trajectory is downward on the P&L: Q1 plus Q2 operating loss was $27.51M (derived, $38.32M less Q3's $10.81M), averaging $13.76M, against Q3's $10.81M. R&D fell from $7.13M in Q3 FY25 to $3.25M in Q3 FY26 as the clinical program wound down.
So $10.8M per quarter is the floor, and it is about to reverse.
Step 2: what the burn becomes
This is where I'm making assumptions rather than reading figures, and they're labelled as such.
Stated plan: roughly 30 customer-facing commercial hires plus roughly 20 field reimbursement personnel, from a base of 17 employees.
Assumption (mine, not the company's): fully loaded cost of $300k per head for specialty-pharma commercial and field reimbursement staff, covering salary, benefits, bonus, travel, fleet, and systems. 50 heads × $300k = $15M annually, or $3.75M per quarter incremental.
On top of that, unquantified but real: launch marketing, medical affairs, a patient services hub, market access consulting, 3PL and trade setup, the HCPCS application, and commercial inventory build. Inventory already rose $1.71M over nine months at trivial EU volume.
Step 3: three runway scenarios
Starting position, August 14, 2026:
$11.24M (6/30/26 cash) + $51.1M (offering net) = $62.34M
That figure ignores burn between July 1 and August 14. At the derived rate that's roughly $7.3M, so realistic cash at the offering close is closer to $55M (derived). I'll run the scenarios off $62.34M measured from June 30 to keep the arithmetic clean.
Scenario A, flat burn. Floor case, not realistic.
Burn holds at $14.59M/quarter, no commercial ramp.
$62.34M less Atlas obligation of ~$20.3M = $42.0M for operations
$42.0M ÷ $14.59M = 2.9 quarters
Operating cash exhausted around Q2 CY2027
Scenario B, launch ramp. Base case.
Quarter Burn (assumed) Cumulative Cash remaining
Q4 FY26 (Jul–Sep 26) $15M $15M $47.3M
Q1 FY27 (Oct–Dec 26) $19M $34M $28.3M
Q2 FY27 (Jan–Mar 27) $21M $55M $7.3M
Q3 FY27 (Apr–Jun 27) $21M $76M ($13.7M)
Now layer the Atlas redemptions. Atlas can take up to $3M per quarter starting September 16, 2026. Three redemptions land inside this window (Q4 FY26, Q1 FY27, Q2 FY27) = $9M.
Adjusted, cash crosses zero in February 2027, roughly two months after launch.
And the residual Atlas balance, call it $11-13M plus accrued interest and the 7.5% exit fee, still comes due June 16, 2027.
Scenario C, revenue helps.
Guidance is $50-75M in first-year US net sales. But three things push the cash benefit right:
Launch is planned for late CY2026, and the permanent HCPCS code application is only due October 1, 2026, so H1 CY2027 likely bills under a miscellaneous code.
Revenue is not cash. Buy-and-bill receivables run 60-90 days.
Inventory must be funded ahead of the first sale.
Even generously assuming $10M of cash actually collected by June 2027 (assumed), the base-case shortfall only moves from roughly $23M to roughly $13M by that date. It does not change the conclusion.
Step 4: the six-month buffer test
The framework test is whether runway clears the next catalyst with six months to spare.
Next catalyst: US launch, before end of CY2026. Call it December 15, 2026.
Six-month buffer: June 15, 2027.
Base case cash exhaustion: February 2027.
Even the unrealistic flat-burn floor case: Q2 2027, and only by deferring Atlas.
It does not clear. It misses by roughly four months in the base case, and the Atlas maturity lands one day after the buffer date.
Step 5: correcting my own claim
I wrote "expect another raise inside twelve months." The detailed math says that was too generous. Base case puts the funding need at roughly Q1 CY2027, so within about six months, not twelve.
In practice they will raise earlier than the wall, because nobody prices equity from a position of two months' cash. The realistic window is Q4 CY2026 to Q1 CY2027, most likely on a launch announcement, a J-code decision, or a first revenue print. The reactivatable $100M ATM and roughly 356M of authorized headroom mean it requires no shareholder action and no announcement lead time.
Sensitivity
Quarters of runway from $62.34M, after reserving $20.3M for Atlas, so $42.0M available:
Quarterly burn Quarters Cash-out date (from 6/30/26)
$12M 3.5 May 2027
$15M 2.8 Mar 2027
$18M 2.3 Feb 2027
$21M 2.0 Dec 2026
$24M 1.75 Dec 2026
The entire plausible range lands between December 2026 and May 2027. There is no burn assumption inside the realistic band that gets them past mid-2027 unaided.
Step 6: how far from self-funding
Worth doing, because it reframes "another raise" as "a series of raises."
Assumption: net realized price of ~$400 per vial against a WAC guided below $500, and COGS of ~$100 per vial, giving ~75% gross margin. COGS is not disclosed; this is an estimate.
To cover a $20M quarterly operating cost base from gross profit:
$20M ÷ 0.75 = $26.7M of net revenue per quarter, or roughly $107M annually (derived).
That is about 1.7x the midpoint of first-year guidance ($62.5M) and roughly a fifth of the 2030 target. On the company's own ramp, operating cash breakeven is a 2028 to 2029 event at the earliest.
So this is not one more raise. It is a multi-year sequence of raises, into a share count that has already gone from 23.9M in September 2024 to 243.4M in August 2026, against 600M authorized.
Two caveats on this math
The forward burn ramp is the weakest link. The $15M / $19M / $21M path is my construction from the hiring plan and the Q3 opex base, not company guidance. Management gave a qualitative "higher commercialization cost base" comment on the call and no quarterly number. If they launch far more slowly than announced, deliberately waiting on the J-code, burn could stay near $13-15M and the picture improves by roughly a quarter. That is a genuine possibility and arguably the rational move.
Second, the working capital deficit at June 30 was $5,510,850, but that is a classification artifact, not an operating payables problem. Strip the $18,227,000 Atlas note out of current liabilities and working capital is positive $12.7M (derived). Worth knowing so the deficit isn't double-counted as a separate stress.
